Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label BI 655130 safety study in ulcerative colitis
NL-OMON48579Phase 2Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of spesolimab in autoimmune colitis, sponsored by Boehringer Ingelheim. Primary endpoint: Exposure-adjusted treatment-emergent adverse reactions. Planned start Aug 2018; status: withdrawn.
02
Drugs
spesolimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON48579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48579.